Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Subscribe To Our Newsletter & Stay Updated